Founded 2022
Founders Maria Teresa Perez Zaballos, CEO, EndoGene.Bio Madeleine Moscatelli, CTO, EndoGene.Bio

Period pain is not normal. But because of undiagnosed endometriosis, it’s a reality for 190 million women globally. At EndoGene.bio, we will be helping women across the world get access to early diagnosis through cutting-edge epigenetics.

Endometriosis affects 10% of women, takes 7 years to diagnose and has high societal and economic costs. In the EU and US alone, the estimated cost of delayed diagnosis reaches €300B. 

This is caused by a lack of specific and early tests. At EndoGene.Bio, we are developing a prescription diagnostic test based on epigenetic biomarkers found in menstrual blood that patients can take in the comfort of their home. 

With this technology, we will reduce time to diagnosis from 7 years to two consultations: one to get your test done, one to get your results.


Founders

Maria Teresa Perez
Zaballos

CEO, EndoGene.Bio

Ex-Merck Fertility Portfolio Expansion Manager. PhD in Medical Devices, & MSc in Biotech Management

Linkedin

Madeleine
Moscatelli

CTO, EndoGene.Bio

PhD & Post-Doc in Genetics & Epigenetics with extensive stem cell experience ex-Université de Paris

Linkedin

Related

47 Labs

47 Labs

Lighting up the brain for healthcare.
A&B Smart Materials

A&B Smart Materials

Revolutionising cooling technology through the development of novel, smart hydrogels.
AarogyaAI

AarogyaAI

AarogyaAI is an AI-enabled SaaS that diagnoses drug-resistant turberculosis (DR-TB) in hours instead of weeks.
Accelerated Dynamics

Accelerated Dynamics

Technology to drive the 4th industrial revolution.
AccuRx

AccuRx

Powering communications in the healthcare sector.
Ackcio

Ackcio

Extremely reliable, wireless monitoring solutions for the world's most challenging industries.